In the future, combination therapies involving traditional chemotherapy drugs and small molecule compounds could be used for drug-resistant colon cancer patients or to enhance therapeutic efficacy, especially in those with high IGF2BP3 expression. This evidence concerns the gene IGF2BP3 and colonic neoplasm.